首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1388197

痛风治疗药物市场、份额、市场规模、趋势、产业分析报告：依药物类别、疾病状态、地区、细分市场预测，2023-2032

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032

出版日期: 2023年10月23日 | 出版商:

Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

根据 Polaris 市场研究的最新研究，到 2032 年，全球痛风药物市场预计将达到 60.4 亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

随着专注于再生疗法的研究和开发的增加，生物製剂正在获得认可。这些创新的治疗方法在解决痛风的症状和根本原因方面显示出巨大的潜力。此外，影像方式的显着进步提高了有效诊断和监测痛风的能力。

此外，对痛风及其危险因子的更好了解也提高了医疗专业人员和患者的认识。痛风主要发生在 40 岁以上的男性，他们的血液中尿酸含量较高。男性比女性更容易患痛风。过量的尿酸会形成针状晶体，引起关节疼痛、发炎和疼痛。

这些综合因素正在推动对有效痛风治疗的需求。製药公司和研究人员正在积极致力于开发新的和改进的治疗方法，以解决痛风症状和长期管理。目标是为患者提供缓解疼痛、减少发炎并防止痛风復发的标靶治疗。

由于生活方式的改变和饮食因素，痛风在全球范围内呈上升趋势，且患者数量不断增加。市场正在见证治疗选择的进步，包括新的药物配方和组合，提供更高的疗效和便利性。

此外，根据患者个别特征客製化治疗的个人化医疗方法也变得越来越流行。意识和诊断率的提高、技术的进步以及新兴市场的扩张进一步促进了市场的成长。主要产业参与者之间的联盟和合作也促进了痛风药物的研究和开发。

痛风治疗市场报告亮点

非类固醇类抗发炎药（NSAIDs）领域以最高份额占据市场主导地位。非类固醇类抗发炎药 (NSAID) 广泛使用、经济高效且在严重痛风发作期间有效，使其成为减轻风湿性和非风湿性疾病发炎和疼痛的可行选择，是首选药物。

慢性病细分市场预计将占据市场上最大的销售份额。该领域的成长是由各种降尿酸药物的推出以及新疗法进入市场的潜力所推动的。

北美在市场上占据主导地位，并打算在预测期内保持其主导地位。痛风影响着北美的许多人，光在美国估计就有 830 万人，盛行率为 1% 至 4%。

主要发现
简介
- 2019-2032 年按地区划分的痛风治疗药物市场评估
痛风药物市场 - 北美
- 北美：痛风药物市场，依疾病状况，2019-2032 年
- 北美：2019-2032 年痛风药物市场，依药物分类
- 痛风药物市场 - 美国
- 痛风药物市场 - 加拿大
痛风药物市场 - 欧洲
- 欧洲：2019-2032 年痛风药物市场，依疾病状态
- 欧洲：2019-2032 年痛风药物市场，依药物分类
- 痛风药物市场 - 英国
- 痛风药物市场 - 法国
- 痛风药物市场－德国
- 痛风药物市场 - 义大利
- 痛风药市场－西班牙
- 痛风药物市场 - 荷兰
- 痛风药物市场 - 俄罗斯
痛风药物市场 - 亚太地区
- 亚太地区：痛风药物市场，依疾病状况，2019-2032 年
- 亚太地区：痛风药物市场，依药物类别，2019-2032 年
- 痛风药物市场－中国
- 痛风药物市场 - 印度
- 痛风药市场 - 马来西亚
- 痛风药物市场－日本
- 痛风药物市场－印度尼西亚
- 痛风治疗药物市场－韩国
痛风药物市场 - 中东和非洲
- 中东和非洲：2019-2032 年痛风药物市场，依疾病状况
- 中东和非洲：2019-2032 年痛风药物市场，依药物类别
- 痛风药物市场－沙乌地阿拉伯
- 痛风药物市场 - 阿拉伯联合大公国
- 痛风药物市场 - 以色列
- 痛风药物市场 - 南非
痛风药物市场 - 拉丁美洲
- 拉丁美洲：痛风药物市场，依疾病状况，2019-2032 年
- 拉丁美洲：痛风药物市场，依药物类别，2019-2032 年
- 痛风药物市场 - 墨西哥
- 痛风药物市场 - 巴西
- 痛风药物市场－阿根廷

第 8 章竞争态势

扩张与收购分析
- 放大
- 收购
伙伴关係/协作/协议/揭露

第 9 章公司简介

Ablynx
Antares Pharma
Astellas Pharma
AstraZeneca
Boehringer Ingelheim
CymaBay Therapeutics
Eisai
Eli Lilly
GlaxoSmithKline
Horizon Pharma
JW Pharmaceutical
LG Life Sciences
Merck
Novartis
Novo Nordisk
Regeneron Pharmaceuticals
Sandoz（a subsidiary of Novartis）
Sanofi
Takeda Pharmaceuticals
Teijin Pharma
Vertex Pharmaceuticals

简介目录图表

Product Code: PM1611

The global gout therapeutics market size is expected to reach USD 6.04 billion by 2032, according to a new study by Polaris market research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biologics has a rising acceptance and increased research and development focused on regeneration therapies. These innovative treatment approaches show great promise in addressing gout's symptoms and underlying causes. Additionally, there have been significant advancements in imaging modalities, which have enhanced the ability to diagnose and monitor gout effectively.

Furthermore, a greater understanding of the disease and its risk factors leads to increased awareness among healthcare professionals and patients. Gout primarily affects men over 40 with high uric acid levels in their blood. Males are more susceptible to developing gout compared to females. Excessive uric acid leads to the formation of needle-like crystals, which can result in joint pain, inflammation, and soreness.

These combined factors have propelled the demand for effective gout therapeutics. Pharmaceutical companies and researchers are actively working to develop new and improved treatment options to address the symptoms and long-term management of gout. The aim is to provide patients with targeted therapies that alleviate pain, reduce inflammation, and prevent recurrent gout attacks.

Gout is growing globally due to lifestyle changes and dietary factors, expanding the patient pool. The market is witnessing advancements in treatment options, including new drug formulations and combinations, offering improved efficacy and convenience.

Additionally, personalized medicine approaches are gaining traction, tailoring treatments based on individual patient characteristics. Rising awareness and diagnosis rates, technological advancements, and expansion in emerging markets further contribute to the market's growth. Collaborations and partnerships among key industry players also facilitate research and development efforts in gout therapeutics.

Gout Therapeutics Market Report Highlights

NSAIDs segment dominated the market with highest share. Due to their widespread availability, cost-effectiveness, and efficacy during severe gout attacks, NSAIDs are the preferred first-line treatment for reducing inflammation and pain in rheumatic and non-rheumatic diseases.

Chronic segment anticipated to hold the largest revenue share of the market. The growth of this segment is fueled by the introduction of various urate-lowering drugs and the potential for new treatments to enter the market.

North America dominated the market and willing to maintain its dominance over the forecast period. Gout affects many people in North America, with an estimated 8.3 million individuals affected in the United States alone and a prevalence rate ranging from 1% to 4%.

The global key market players include: Ablynx, Antares Pharma, CymaBay Therapeutics, Astellas Pharma, AstraZeneca, Horizon Pharma, Boehringer Ingelheim, Merck, Eisai, Regeneron Pharmaceuticals, Eli Lilly and others.

Polaris market research has segmented the gout therapeutics market report based on drug class, disease condition, and region:

Gout Therapeutics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate Lowering Agents

Gout Therapeutics, Disease Condition Outlook (Revenue - USD Billion, 2019 - 2032)

Acute
Chronic

Gout Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Gout Therapeutics Market Insights

4.1. Gout Therapeutics Market - Industry Snapshot
4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing prevalence of gout worldwide
  - 4.2.1.2. Continuous research and development activities
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Cost of treatment
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Gout Therapeutics Industry trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Gout Therapeutics Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Gout Therapeutics, by Drug Class, 2019-2032 (USD Billion)
5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs) by Region, 2019-2032 (USD Billion)
5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2019-2032 (USD Billion)
5.6. Urate Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2019-2032 (USD Billion)

6. Global Gout Therapeutics Market, by Disease Condition

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
6.3. Acute
- 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2019-2032 (USD Billion)
6.4. Chronic
- 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2019-2032 (USD Billion)

7. Global Gout Therapeutics Market, by Geography

7.1. Key findings
7.2. Introduction
- 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
7.3. Gout Therapeutics Market - North America
- 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.3. Gout Therapeutics Market - U.S.
  - 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.3.4. Gout Therapeutics Market - Canada
  - 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.4. Gout Therapeutics Market - Europe
- 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.3. Gout Therapeutics Market - UK
  - 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.4. Gout Therapeutics Market - France
  - 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.5. Gout Therapeutics Market - Germany
  - 7.4.5.1. Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.6. Gout Therapeutics Market - Italy
  - 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.7. Gout Therapeutics Market - Spain
  - 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.8. Gout Therapeutics Market - Netherlands
  - 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.4.9. Gout Therapeutics Market - Russia
  - 7.4.9.1. Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.4.9.2. Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.5. Gout Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.3. Gout Therapeutics Market - China
  - 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.4. Gout Therapeutics Market - India
  - 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.5. Gout Therapeutics Market - Malaysia
  - 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.6. Gout Therapeutics Market - Japan
  - 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.7. Gout Therapeutics Market - Indonesia
  - 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.7.2. Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.5.8. Gout Therapeutics Market - South Korea
  - 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.6. Gout Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.3. Gout Therapeutics Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.4. Gout Therapeutics Market - UAE
  - 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.5. Gout Therapeutics Market - Israel
  - 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.6.6. Gout Therapeutics Market - South Africa
  - 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
7.7. Gout Therapeutics Market - Latin America
- 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.3. Gout Therapeutics Market - Mexico
  - 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.4. Gout Therapeutics Market - Brazil
  - 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
- 7.7.5. Gout Therapeutics Market - Argentina
  - 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  - 7.7.5.2. Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Ablynx
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Antares Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Astellas Pharma
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Boehringer Ingelheim
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. CymaBay Therapeutics
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Eisai
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Eli Lilly
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. GlaxoSmithKline
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Horizon Pharma
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
9.11. JW Pharmaceutical
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
9.12. LG Life Sciences
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
9.13. Merck
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
9.14. Novartis
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
9.15. Novo Nordisk
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
9.16. Regeneron Pharmaceuticals
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
9.17. Sandoz (a subsidiary of Novartis)
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
9.18. Sanofi
- 9.18.1. Company Overview
- 9.18.2. Financial Performance
- 9.18.3. Product Benchmarking
- 9.18.4. Recent Development
9.19. Takeda Pharmaceuticals
- 9.19.1. Company Overview
- 9.19.2. Financial Performance
- 9.19.3. Product Benchmarking
- 9.19.4. Recent Development
9.20. Teijin Pharma
- 9.20.1. Company Overview
- 9.20.2. Financial Performance
- 9.20.3. Product Benchmarking
- 9.20.4. Recent Development
9.21. Vertex Pharmaceuticals
- 9.21.1. Company Overview
- 9.21.2. Financial Performance
- 9.21.3. Product Benchmarking
- 9.21.4. Recent Development

简介目录图表

List of Tables

Table 1 Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 2 Global Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 3 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
Table 4 North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 5 North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 6 U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 7 U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 8 Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 9 Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 10 Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 11 Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 12 UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 13 UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 14 France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 15 France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 16 Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 17 Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 18 Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 19 Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 20 Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 21 Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 22 Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 23 Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 24 Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 25 Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 26 Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 27 Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 28 China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 29 China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 30 India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 31 India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 32 Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 33 Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 34 Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 35 Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 36 Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 37 Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 38 South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 39 South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 40 Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 41 Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 42 Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 43 Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 44 UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 45 UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 46 Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 47 Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 48 South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 49 South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 50 Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 51 Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 52 Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 53 Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 54 Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 55 Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
Table 56 Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
Table 57 Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

List of Figures

Figure 1 Global Gout Therapeutics Market, 2019-2032 (USD Billion)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
Figure 4 Market by Geography
Figure 5 Porter's Five Forces
Figure 6 Market by Disease Condition
Figure 7 Global Gout Therapeutics Market, by Disease Condition, 2022 & 2032 (USD Billion)
Figure 8 Market by Drug Class
Figure 9 Global Gout Therapeutics Market, by Drug Class, 2022 & 2032 (USD Billion)
Figure 10 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
Figure 11 Strategic Analysis - Gout Therapeutics Market